View all newsletters
Receive our newsletter – data, insights and analysis delivered to you
  1. News
April 20, 2017

Lion Biotechnologies and MD Anderson to investigate TIL therapy in solid tumour trials

Lion Biotechnologies has entered a multi-year strategic alliance agreement with the University of Texas MD Anderson Cancer Center to investigate its tumour-infiltrating lymphocyte (TIL) therapy in multi-arm clinical trials to treat ovarian and pancreatic cancer, as well as different sarcomas.

Lion Biotechnologies has entered a multi-year strategic alliance agreement with the University of Texas MD Anderson Cancer Center to investigate its tumour-infiltrating lymphocyte (TIL) therapy in multi-arm clinical trials to treat ovarian and pancreatic cancer, as well as different sarcomas.

Free Whitepaper
img

Unlocking the clinical trial potential of Africa

Ongoing improvements around infrastructure, continued investment, and being home to one of the world’s largest working age populations, means that Africa’s role in the clinical trials market has transformed. In this whitepaper, Oximio outlines the dynamics of today’s clinical trial market in Africa, including the key challenges the region is facing and how sponsors can overcome them to unlock the continent’s growing potential.
by Oximio
Enter your details here to receive your free Whitepaper.

Based on Lion's TIL technology, the TIL therapy leverages the ability of TILs to overcome the cancer's immunosuppressive effects.

The clinical trials are to be designed by the Lion and MD Anderson joint steering committee and will be conducted by MD Anderson for assessing the safety and efficacy of TIL therapy, developed using two different TIL manufacturing processes.

Both firms will hold the manufacturing responsibilities for producing TILs that will be used in the planned cellular therapy trials.

"We are excited to form this strategic alliance with MD Anderson."

Lion Biotechnologies president and chief executive officer Maria Fardis said: "We are excited to form this strategic alliance with MD Anderson.

"Together, we expect to generate data that will support the pursuit of additional pipeline indications to complement our ongoing Lion-sponsored TIL clinical programmes in metastatic melanoma, head and neck and cervical cancers."

The partnership will utilise Lion's expertise in TIL therapy and manufacturing capacity in combination with MD Anderson's experience in novel methods development for TIL generation.

The firms will also engage in a related preclinical research that will aim to expand TIL from other tumour types to identify new indications for clinical research in the future.

TIL therapy is also being studied in clinical trials at the National Cancer Institute and Moffitt Cancer Center.

Related Companies

Free Whitepaper
img

Unlocking the clinical trial potential of Africa

Ongoing improvements around infrastructure, continued investment, and being home to one of the world’s largest working age populations, means that Africa’s role in the clinical trials market has transformed. In this whitepaper, Oximio outlines the dynamics of today’s clinical trial market in Africa, including the key challenges the region is facing and how sponsors can overcome them to unlock the continent’s growing potential.
by Oximio
Enter your details here to receive your free Whitepaper.

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. Key drug pipeline and competitive landscape changes based on the latest clinical activity, sent every Tuesday. Curated analysis and data-driven insights on clinical trials strategy and operations, sent every Thursday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU

Thank you for subscribing to Clinical Trials Arena